KAYNAKLAR
1. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem. 1994;55(3):287-99. 2. Arino H, Kramer HH. Fission product 99mTc generator. Int J Appl Radiat Isot. 1975;26(5):301-3. 3. Asikoglu M, Durak FG. The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m. Appl Radiat Isotopes. 2009;67(9):1616-21. 4. Becker W. Guidelines for Gallium-67 citrate scintigraphy in inflammatory diseases. Nuklearmed. 1999;38(6A):247-8. 5. Bevan JA, Tofe AJ, Benedict JJ, Francis MD, Barnett BL. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model. J Nucl Med. 1980;21(10):967-70. 6. Bhatnagar A, Mishra P, Sharma R, Chuttani K, Chakravarty K, Jain CM, et al. 99mTc-Citrate: a new bone imaging radiopharmaceutical. Nucl Med Commun. 1999;20(11):1067-76. 7. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229-38. 8. Boyd RE. Tc-99m Generators – Prospects for developing nuclear countries facilities. Appl Radiat Isotopes. 1986;37(6):551-. 9. Britton KE. Nuclear medicine imaging in bone metastases. Cancer Imaging. 2002;2:84-6. 10. Calleja M, Alam A, Wilson D, Bradley K. Basic science: nuclear medicine in skeletal imaging. Curr Orthopaed. 2005;19(1):34-9. 11. Caner B, Kitapcl M, Unlu M, Erbengi G, Calikoglu T, Gogus T, et al. Technetium99m-MIBI uptake in benign and malignant bone-lesions – a Comparative-study with Technetium-99m-MDP. J Nucl Med. 1992;33(3):319-24. 12. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician. 2001;63(12):2413-20. 13. Chan G, Mckay WJ, Miller BR, Shilson AD. Radiopharmaceutical cold kit production – a pharmacists view. Aust Nz J Med. 1983;13(6):665-. 14. Chen TL, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228-36. 15. Cornud F, Oyen R. Role of imaging in the diagnosis and staging of prostatic adenocarcinomas. J Radiol. 2002;83(6 Pt 2):863-80, discussion 81-2. 16. Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15(8):1467-76. 17. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. Bju Int. 2004;94(1):164-70. 18. Çetin Önsel FK, (Ed) Görütüleme Yöntemleri Sempozyumu 1. Basım ed. İstanbul 2010. 19. Dennis L. Nosco JAB-N. Chemistry of technetium radiopharmaceuticals 1: Chemistry behind the development of technetium-99m compounds to determine kidney function. Coordination Chemistry Reviews. 1999(184):91123. 20. Diezjimenez L, Gutierrezgonzalez ME, Guitianiglesias R, Borrellmerlin MP, Llovetverdugo A, Arnaizbueno F. Clinical uses of Thalium-201 myocardial imaging. Rev Clin Esp. 1980;157(6):381-5. 21. Durak FG. Kemik Sintigrafisi İçin Yeni 99mTc Bifosfonat Radyofarmasötiklerinin Geliştirilmesi [Yüksek Lisans Tezi]. İzmir: Ege Üniversitesi, Sağlık Bilimleri Enstitüsü; 2005. 22. Elliott A. Medical imaging. Nucl Instrum Meth A. 2005;546(1-2):1-13.
140



153. SAYFAYA BENZER SAYFALAR

tabs_sener_yagiz_191898 - Sayfa
...


153. SAYFA ICERIGI

KAYNAKLAR
1. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem. 1994;55(3):287-99. 2. Arino H, Kramer HH. Fission product 99mTc generator. Int J Appl Radiat Isot. 1975;26(5):301-3. 3. Asikoglu M, Durak FG. The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m. Appl Radiat Isotopes. 2009;67(9):1616-21. 4. Becker W. Guidelines for Gallium-67 citrate scintigraphy in inflammatory diseases. Nuklearmed. 1999;38(6A):247-8. 5. Bevan JA, Tofe AJ, Benedict JJ, Francis MD, Barnett BL. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model. J Nucl Med. 1980;21(10):967-70. 6. Bhatnagar A, Mishra P, Sharma R, Chuttani K, Chakravarty K, Jain CM, et al. 99mTc-Citrate: a new bone imaging radiopharmaceutical. Nucl Med Commun. 1999;20(11):1067-76. 7. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229-38. 8. Boyd RE. Tc-99m Generators – Prospects for developing nuclear countries facilities. Appl Radiat Isotopes. 1986;37(6):551-. 9. Britton KE. Nuclear medicine imaging in bone metastases. Cancer Imaging. 2002;2:84-6. 10. Calleja M, Alam A, Wilson D, Bradley K. Basic science: nuclear medicine in skeletal imaging. Curr Orthopaed. 2005;19(1):34-9. 11. Caner B, Kitapcl M, Unlu M, Erbengi G, Calikoglu T, Gogus T, et al. Technetium99m-MIBI uptake in benign and malignant bone-lesions – a Comparative-study with Technetium-99m-MDP. J Nucl Med. 1992;33(3):319-24. 12. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician. 2001;63(12):2413-20. 13. Chan G, Mckay WJ, Miller BR, Shilson AD. Radiopharmaceutical cold kit production – a pharmacists view. Aust Nz J Med. 1983;13(6):665-. 14. Chen TL, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228-36. 15. Cornud F, Oyen R. Role of imaging in the diagnosis and staging of prostatic adenocarcinomas. J Radiol. 2002;83(6 Pt 2):863-80, discussion 81-2. 16. Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15(8):1467-76. 17. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. Bju Int. 2004;94(1):164-70. 18. Çetin Önsel FK, (Ed) Görütüleme Yöntemleri Sempozyumu 1. Basım ed. İstanbul 2010. 19. Dennis L. Nosco JAB-N. Chemistry of technetium radiopharmaceuticals 1: Chemistry behind the development of technetium-99m compounds to determine kidney function. Coordination Chemistry Reviews. 1999(184):91123. 20. Diezjimenez L, Gutierrezgonzalez ME, Guitianiglesias R, Borrellmerlin MP, Llovetverdugo A, Arnaizbueno F. Clinical uses of Thalium-201 myocardial imaging. Rev Clin Esp. 1980;157(6):381-5. 21. Durak FG. Kemik Sintigrafisi İçin Yeni 99mTc Bifosfonat Radyofarmasötiklerinin Geliştirilmesi [Yüksek Lisans Tezi]. İzmir: Ege Üniversitesi, Sağlık Bilimleri Enstitüsü; 2005. 22. Elliott A. Medical imaging. Nucl Instrum Meth A. 2005;546(1-2):1-13.
140




single.php